Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.

Oct 24, 2023

  • Corporate

Chugai Announces 2023 3rd Quarter Results

  • Core revenue and core operating profit for the first nine months at ¥837.6 billion (+14.8%) and ¥340.5 billion (+13.9%), respectively
  • Steady progress in R&D activities for in-house projects, mainly in late-stage development, including acceptance of approval application of crovalimab for the treatment of paroxysmal nocturnal hemoglobinuria in the U.S., achievement of the primary endpoint in a phase III study of Alecensa for the adjuvant treatment of early-stage ALK-positive non-small cell lung cancer, and initiation of a phase III study of Enspryng for a new indication
TOKYO, October 24, 2023 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced its financial results for the third quarter of fiscal year 2023.

“In the third quarter of this year, we saw a continuation of the increase in both revenue and profits on a Core-basis from the first half. Sales increased both in domestic and overseas, driven by steady growth in new products such as Polivy®, Vabysmo® in Japan and by more than double-digit growth overseas in mainstay products Hemlibra® and Alecensa®. In R&D, Chugai made steady progress with in-house projects, mainly in late-stage development. An application for crovalimab in the treatment of paroxysmal nocturnal hemoglobinuria (PNH) was accepted for filing in the U.S. In addition, Alecensa achieved its primary endpoint in a global phase III study as a post-operative adjuvant therapy for early-stage ALK-positive non-small cell lung cancer (NSCLC), and Enspryng® started a global phase III study for thyroid ophthalmopathy (TED), its fifth indication, and is being simultaneously developed in multiple diseases. We will continue to drive innovation to deliver innovative new drugs to patients as quickly as possible,” said Dr. Osamu Okuda, Chugai’s President and CEO.

< Third Quarter Financial Results (Core results, January to September 2023) >

Chugai reported increased revenue and operating profit for the first nine months (Core-basis) compared to the same period of the previous fiscal year, consistent with second-quarter results.

Revenue increased in approximately 15% overall, with growth in both domestic and overseas sales and other revenue. Domestic sales increased by approximately 10%. In the oncology field, the growth was approximately 3% year-on-year due to the contribution of steady market penetration of new product Polivy, and the growth of mainstay product Tecentriq® despite the impact of biosimilars and NHI drug price revisions on mature products such as Avastin® and Herceptin®. In the specialty field, sales increased by approximately 20%, driven by the penetration of new products Vabysmo for ophthalmology and Evrysdi® for neuroscience, as well as the contribution of mainstay products Hemlibra for hemophilia and Enspryng for neuroscience, and the supply of Ronapreve® for COVID-19 treatment to the government in the first quarter. Overseas sales increased by approximately 20% due to solid growth in exports of Hemlibra and Alecensa. Other revenue increased by approximately 13%, mainly due to the increase in royalties and profit-sharing income related to Hemlibra. Revenue on IFRS basis, including Non-Core items, decreased due to the one-time impact of the lump-sum income from the settlement agreement with Alexion Pharmaceuticals, Inc in the previous year.

Cost to sales ratio rose by 2.4% points year-on-year to 43.1%, mainly due to the impact of foreign exchange. Research and development expenses increased due to investments into drug discovery and early development, including the start of operation of Chugai Life Science Park Yokohama, and the progress of development projects. Also selling, general and administration expenses increased mainly due to various expenses. For other operating income (expense), an income of ¥16.3 billion was recorded, mainly due to the recognition of income from disposal of product rights and gain on sale of property, plant and equipment. As a result, Core operating profit totaled ¥340.5 billion (+13.9%).

<R&D activities>

The company also made good progress in research and development. Among our in-house projects, Actemra obtained approval for an additional indication of cytokine release syndrome induced by cancer therapy. Late-stage projects progressed including the U.S. Food and Drug Administration (FDA) acceptance of application of crovalimab for the treatment of PNH, and Alecensa achieving the primary endpoint in a global phase III study in patients with early-stage ALK-positive NSCLC, demonstrating the efficacy in adjuvant therapy for the first time as an ALK inhibitor. A global phase III study for Enspryng for treatment of TED, an ophthalmic disease, has been initiated. The drug is now being developed for four diseases simultaneously. As for projects in-licensed from Roche, Phesgo®, a subcutaneous combination of Perjeta and Herceptin, which are standard treatments for HER2-positive breast cancer administered by intravenous injections, has received approval in Japan as a treatment for HER2-positive breast cancer and colorectal cancer. In addition, a new immune checkpoint inhibitor tobemstomig (RG6139) in solid tumors has entered the pipeline.

[2023 third quarter results]

Billion JPY2023
Jan - Sep
Jan - Sep
% change
Core results
 Revenue 837.6 729.3 +14.8%
  Sales 742.1 644.7 +15.1%
  Other revenue 95.5 84.6 +12.9%
 Operating profit 340.5 299.0 +13.9%
 Net income 250.3 213.0 +17.5%
IFRS results*
 Revenue 837.6 821.2 +2.0%
 Operating profit 317.6 383.8 -17.2%
 Net income 234.3 271.9 -13.8%

*IFRS results in 2022 include non-Core items, such as the income and other related items, which totaled ¥90.7 billion associated with the settlement agreement between Chugai and Alexion Pharmaceuticals, Inc., which are excluded from the Core results Chugai adopts to manage recurring business activities.

[Sales breakdown]

Billion JPY2023
Jan - Sep
Jan - Sep
% change
 Domestic sales 429.2 387.6 +10.7%
  Oncology 191.4 186.5 +2.6%
  Specialty 237.9 201.0 +18.4%
 Overseas sales 312.9 257.1 +21.7%

[Oncology field (Domestic) Top5-selling medicines]

Billion JPY2023
Jan - Sep
Jan - Sep
% change
 Tecentriq 47.9 43.9 +9.1%
 Avastin 38.2 50.9 -25.0%
 Polivy 25.5 9.1 +180.2%
 Perjeta 24.6 23.5 +4.7%
 Alecensa 22.0 20.9 +5.3%

[Specialty field (Domestic) Top5-selling medicines]

Billion JPY2023
Jan - Sep
Jan - Sep
% change
 Ronapreve* 81.2 60.8 +33.6%
 Hemlibra 40.5 35.2 +15.1%
 Actemra 32.2 31.2 +3.2%
 Enspryng 16.9 11.5 +47.0%
 Vabysmo 10.8 3.2 +237.5%

*Ronapreve has not been listed in the National Health Insurance (NHI) price list.

[Progress in R&D activities from Jul 28th, 2023 to Oct 24th, 2023]

2023 Q3 R&D Progress

About Core results

Chugai discloses its results on a Core basis from 2013 in conjunction with its decision to apply IFRS. Core results are the results after adjusting Non-Core items to IFRS results. Chugai’s recognition of non-recurring items may differ from that of Roche due to the difference in the scale of operations, the scope of business and other factors. Core results are used by Chugai as an internal performance indicator, for explaining the underlying business performance both internally and externally, and as the basis for payment-by-results such as a return to shareholders.

Trademarks used or mentioned in this release are protected by law.


  • For Media
  • Chugai Pharmaceutical Co., Ltd.
  • Media Relations Group, Corporate Communications Dept.,
  • Hideki Sato
  • Tel: +81-3-3273-0881
  • E-mail:
  • For Investors
  • Chugai Pharmaceutical Co., Ltd.
  • Investor Relations Group, Corporate Communications Dept.,
  • Takayuki Sakurai
  • Tel: +81-3-3273-0554
  • E-mail:
  • Like
  • Post
  • LINE it!
  • E-mail
Back to top